Business · 17/04/2002Updated: 10/17/2026 · 1 min read
FDA Extends Comment Period for MIFEPREX Patent Extension
Summary
The Food and Drug Administration (FDA) has extended the comment period for the regulatory review period determination for MIFEPREX until April 26, 2002, in response to a request for an extension.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →